Please assess the completion status of the following clinical trial:

Trial Title: Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed intracranial glioblastoma multiforme (GBM)~  * Original diagnosis of low-grade glioma with subsequent histological confirmation of GBM allowed~ * Recurrent disease~    * Failed prior radiotherapy~* Must require a surgical procedure (gross total or near gross total resection) for tumor removal~* Performance status - Karnofsky 60-100%~* White Blood Count (WBC) ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL (transfusion allowed)~* Serum glutamic oxaloacetic transaminase (SGOT) \< 2 times upper limit of normal (ULN)~* Bilirubin \< 2 times ULN~* Creatinine \< 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for ≥ 2 weeks after study participation (for female patients) or for 3 months after study participation (for male patients)~* No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No active infection~* No other significant uncontrolled medical illness that would preclude study participation~* At least 3 weeks since prior interferon~* No prior cilengitide~* No other prior targeted antiangiogenic treatment (e.g., vatalanib, SU5416, or thalidomide)~* No concurrent anticancer immunotherapy~* No concurrent routine prophylactic filgrastim (G-CSF)~* At least 2 weeks since prior vincristine~* At least 3 weeks since prior procarbazine~* At least 6 weeks since prior nitrosoureas~* No concurrent anticancer chemotherapy~* At least 3 weeks since prior tamoxifen~* No concurrent anticancer hormonal therapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy~* No concurrent anticancer radiotherapy~* Recovered from all prior therapies~* No more than 3 prior treatments for GBM (1 initial treatment; and treatment for 2 relapses)~  * For patients who received prior therapy for low-grade glioma, a subsequent surgical diagnosis of high-grade glioma is considered the first relapse~* At least 4 weeks since prior investigational agents~* At least 4 weeks since prior cytotoxic therapy~* At least 3 weeks since other prior non-cytotoxic therapy (e.g., isotretinoin), except radiosensitizers~* No other concurrent anticancer therapy~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I (high-dose cilengitide) 2000mg (Type: EXPERIMENTAL): Preoperative Treatment: Patients receive high-dose cilengitide IV over 1 hour on days -8, -4, and -1. (High dose 2000mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
- Group II (low-dose cilengitide) 500mg (Type: EXPERIMENTAL): Preoperative Treatment: Patients receive low-dose cilengitide IV over 1 hour on days -8, -4, and -1. (500mg)~Resection: All patients undergo tumor resection on day 0.~Postoperative Treatment: Beginning within 2 weeks after surgery, all patients receive high-dose cilengitide IV over 1 hour twice weekly for 4 weeks. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).